Logo

Vermillion

Aspira Collaborating With Baylor Genetics on Ovarian Cancer Early Detection Test

Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.

Aspira Eyes $11M in Private Equity Financing

Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.

Aspira Labs to Evaluate GenomeSmart Genetic Test Recommendation Platform

The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.

Vermillion Q4 Revenues Up 123 Percent

The company posted an 11 percent year-over-year decline in OVA1 sales but more than doubled its average revenue per test, to $301 from $143 in Q4 2015.

Vermillion, Quest Extend, Amend Ovarian Cancer Test Deal

The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal.

Mar 7, 2017

Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1

Mar 2, 2017

Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1

Feb 14, 2017

Vermillion Aims to Raise $10.7M

Nov 10, 2016

Vermillion Q3 Revenues Up 89 Percent

Sep 29, 2016

Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1

Aug 19, 2016

Vermillion Hoping New Service Business Will Boost Revenue Growth
Premium

Aug 10, 2016

Vermillion Q2 Revenues Up 33 Percent, OVA1 Sales Down

May 16, 2016

Vermillion Q1 Revenues Down 47 Percent

Apr 28, 2016

Clinical Utility Study Finds Vermillion's OVA1 Useful in Driving High-Risk Patients to Specialists

Apr 18, 2016

Vermillion Receives First $2M of $4M Loan From State of Connecticut

Mar 24, 2016

Vermillion Posts $361K in Q4 Revenues, Large Drop in OVA1 Sales Volume

Mar 21, 2016

Vermillion Receives FDA 510(k) Clearance for Overa

Feb 11, 2016

Vermillion Launching Pelvic Mass Registry With $7.5M From CPRIT

Jan 22, 2016

Consortium Publishes Study on Ultrasound Approach to Evaluate Adnexal Masses
Premium

Dec 1, 2015

Vermillion Wins Medi-Cal Coverage for OVA1

Nov 20, 2015

Vermillion's Kaiser Collaboration Could Hold Keys to Broadening OVA1 Uptake
Premium

Nov 12, 2015

Vermillion Q3 Revenues Up 2 Percent

Oct 30, 2015

With CE Mark, Vermillion Moving Toward Commercialization of Overa Test
Premium

Oct 26, 2015

Vermillion Receives CE Mark for Overa

Aug 19, 2015

CareFirst BlueCross/Blue Shield to Cover Vermillion's OVA1

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.